Director Myron Kaplan filed a Form 4 with the SEC on November 18, 2026, disclosing a purchase of 25,000 shares of CorMedix Inc. common stock on November 16, 2026.
Key Highlights
- Purchase date: Myron Kaplan acquired 25,000 shares of CorMedix Inc. common stock on November 16, 2026.
- Weighted average price: The transaction was recorded at a weighted average price of $4.88 per share, with individual trades ranging from $4.87 to $4.88.
- Direct ownership after transaction: Following the purchase, Kaplan directly beneficially owns 256,487 shares of common stock.
- Indirect holdings: The filing also reports 20,000 shares held indirectly through a spouse and 10,000 shares held indirectly through a spouse as guardian for grandchildren, with Kaplan disclaiming beneficial ownership of both.
- Transaction code: The transaction was coded "P" (open-market purchase) with no Rule 10b5-1 plan indicated.
Kaplan's November 2026 Open-Market Purchase of CorMedix Common Stock
According to the Form 4 filed with the SEC, Myron Kaplan, a director of CorMedix Inc. (NASDAQ:CRMD), purchased 25,000 shares of the company's common stock on November 16, 2026. The filing states the transaction was executed in multiple trades at prices ranging from $4.87 to $4.88 per share, with $4.88 reported as the weighted average price. The filing notes that Kaplan "hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."
Following this acquisition, the filing reports Kaplan's direct beneficial ownership at 256,487 shares of CorMedix common stock. In addition, the filing discloses two indirect holdings: 20,000 shares held through a spouse, and 10,000 shares held through a spouse acting as guardian for grandchildren. For both indirect positions, the filing states that Kaplan "disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."
The Form 4 was signed by Beth Zelnick Kaufman as attorney-in-fact on November 18, 2026. No Rule 10b5-1 trading plan box was checked in connection with this transaction, and no derivative securities activity was reported in Table II of the filing.
What Was Disclosed
The filing disclosed an open-market purchase of 25,000 CorMedix common shares by director Myron Kaplan on November 16, 2026, at a weighted average price of $4.88, bringing his direct holdings to 256,487 shares. Two indirectly held positions totaling 30,000 shares were also reported, with beneficial ownership disclaimed for both.




Please wait processing your request...